Anti-Cancer Agents in Medicinal Chemistry

Author(s): Zhichao Song, Chunhui Wang, Fei Ding, Hao Zou and Chengkui Liu*

DOI: 10.2174/1871520623666221103110934

DownloadDownload PDF Flyer Cite As
Ganoderic Acid A Enhances Tumor Suppression Function of Oxaliplatin via Inducing the Cytotoxicity of T Cells

Page: [832 - 838] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Background: Various natural products have been demonstrated for their anti-tumor activities. As a natural triterpenoid, the effects of ganoderic acid A on oxaliplatin chemotherapy for cancer treatment remain unclear.

Methods: A xenograft mouse model of colon cancer was constructed using the HT-29 cells. Ganoderic acid A was intravenously administered with or without oxaliplatin. The CCK-8 method was performed to assess cell viability. Flow cytometry was used to determine cell apoptosis and subtyping of T cells. Cytotoxicity of the T cells was assayed using a lymphocyte-tumor co-culture system in vitro.

Results: Ganoderic acid A enhanced tumor suppression of oxaliplatin in the xenograft model, while single administration showed no obvious anti-tumor effect. Ganoderic acid A didn’t affect cell proliferation and apoptosis of HT-29 cells treated by oxaliplatin in vitro. Additionally, ganoderic acid A co-administered with oxaliplatin didn’t impact T cell subtyping in the xenograft model. Cytotoxicity of T cells in co-administered mice was remarkably enhanced compared with oxaliplatin-treated mice.

Conclusion: Our findings reveal that ganoderic acid A synergistically enhances tumor suppression of oxaliplatin possibly via increasing the cytotoxicity of T cells.

Keywords: Colon cancer, ganoderic acid A, oxaliplatin, tumor suppression, T lymphocyte, cytotoxicity.